logo
#

Latest news with #IpratropiumBromideNasalSolution

Lupin launches Ipratropium Bromide Nasal Solution in US market
Lupin launches Ipratropium Bromide Nasal Solution in US market

Business Standard

timea day ago

  • Health
  • Business Standard

Lupin launches Ipratropium Bromide Nasal Solution in US market

Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older. Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).

Lupin launches nasal spray in US, part of 200-drug pipeline by FY30
Lupin launches nasal spray in US, part of 200-drug pipeline by FY30

Business Standard

timea day ago

  • Business
  • Business Standard

Lupin launches nasal spray in US, part of 200-drug pipeline by FY30

Indian pharmaceutical major Lupin on Thursday announced the launch of a new nasal spray — Ipratropium Bromide Nasal Solution — in the United States market. The product is available in two strengths: 0.03 per cent and 0.06 per cent. The company stated that the spray is used to treat runny nose (rhinorrhoea) caused by allergies, the common cold or other non-allergic conditions. It is suitable for both adults and children, depending on the prescribed strength. The product is the generic version of a nasal spray called Atrovent, which is already available in the US market. The spray is considered bioequivalent, meaning it acts in the same way in the body as the reference drug. Lupin has a strong presence in the US and European pharmaceutical markets. As reported by Business Standard in May, the company is targeting a greater share of revenue from its complex generics portfolio in the US and Europe. With a pipeline of over 200 products over the next five years, Lupin expects the revenue share from complex generics to reach 62 per cent by FY30. The contribution from such products is projected at 21 per cent by FY26. Complex generics include high-value products such as inhalers, injectables, transdermal patches and ophthalmic solutions, which typically contain more sophisticated active ingredients and delivery mechanisms. Generic drugs are copies of branded medicines that have gone off-patent. Complex generics differ from simple generics in terms of formulation, technology and margin potential. On Friday, Lupin's shares closed at ₹1,978 on the Bombay Stock Exchange, up ₹22.40 or 1.15 per cent.

Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States
Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States

Business Standard

timea day ago

  • Business
  • Business Standard

Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States

Lupin has announced the launch of Ipratropium Bromide Nasal Solution (nasal spray) in two strengths in the United States. Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc. The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip added 1.36% to end at Rs 1982.20 on the BSE today.

Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market
Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market

Business Upturn

timea day ago

  • Business
  • Business Upturn

Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market

Lupin Limited has announced the launch of its generic version of Ipratropium Bromide Nasal Solution in the United States. The product will be available in both 0.03% and 0.06% strengths and is a therapeutic equivalent to Boehringer Ingelheim's Atrovent® Nasal Spray. This launch marks Lupin's latest addition to its U.S. generic portfolio. The Ipratropium Bromide Nasal Solution 0.03% is used to provide symptomatic relief of rhinorrhea linked to both allergic and nonallergic perennial rhinitis in adults and children aged six and above. The 0.06% version targets rhinorrhea symptoms associated with the common cold or seasonal allergic rhinitis in adults and children aged five and older. According to IQVIA data for the 12 months ending May 2025, the reference drug Atrovent® recorded estimated annual U.S. sales of approximately USD 63 million. With this launch, Lupin aims to tap into the niche respiratory care segment while expanding access to affordable treatment options for patients in the U.S. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store